Albireo Pharma, Inc. (NASDAQ:ALBO) – Stock analysts at William Blair dropped their Q1 2018 earnings per share estimates for shares of Albireo Pharma in a research note issued on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings of ($0.92) per share for the quarter, down from their previous estimate of $0.47.
A number of other research firms have also issued reports on ALBO. Zacks Investment Research upgraded shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research note on Wednesday, October 25th. Roth Capital started coverage on shares of Albireo Pharma in a research note on Wednesday, November 15th. They set a “buy” rating and a $92.00 price objective on the stock. Cowen reiterated a “buy” rating on shares of Albireo Pharma in a research note on Friday, November 17th. Wedbush reiterated an “outperform” rating and set a $58.00 price objective on shares of Albireo Pharma in a research note on Monday, September 11th. Finally, ValuEngine downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Albireo Pharma currently has a consensus rating of “Buy” and an average price target of $54.50.
In other news, major shareholder Plc Astrazeneca sold 500,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $21.40, for a total transaction of $10,700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.30% of the stock is currently owned by company insiders.
Albireo Pharma Company Profile
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.